Novo Nordisk A/S

New York Stock Exchange
Back to all articles
Somewhat Bullish +50

Novo to share real-world and clinical data in...

AI-generated analysis

📅 Novo Nordisk will present new cardiometabolic data at the EASD 2026 meeting in Milan from September 28 to October 2.

🧬 The company will showcase real-world evidence for the Wegovy® pill regarding appetite regulation and eating behavior.

🧠 fMRI data will be shared exploring brain responses to food cues and CagriSema's impact on body composition.

🩺 Novo will present findings on semaglutide addressing excess liver fat in patients with obesity.

⚖️ A comparative study will be presented on major adverse cardiovascular events between escalating to semaglutide 2.0 mg and switching to tirzepatide.

💊 Oral presentations will cover CagriSema, zenagamtide, Wegovy®, and UBT251 across diabetes and obesity indications.

🗣️ Martin Holst Lange highlighted the potential of these findings to shape future cardiometabolic care strategies.

📡 An International Press Briefing is scheduled for September 30, 2026, available via webcast on the Novo website.

Bullish Signals
  • Novo Nordisk is advancing its cardiometabolic portfolio with new real-world data and clinical insights presented at EASD 2026.
  • The company is demonstrating broad benefits of semaglutide across multiple indications, including obesity, type 2 diabetes, and liver health.
Full Analysis
Novo Nordisk announced it will present new data from its cardiometabolic pipeline at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, running from September 28 to October 2, 2026. The presentations cover a broad range of scientific insights related to obesity, type 2 diabetes, cardiovascular health, kidney disease, and liver outcomes, reflecting the company's strategic focus on interconnected cardiometabolic diseases. Key highlights include real-world evidence for the Wegovy® pill regarding appetite regulation and eating behavior, alongside fMRI data exploring brain responses to food cues. Additionally, Novo will share CagriSema data in type 2 diabetes focusing on body composition and organ-level fat remodelling mechanisms, as well as new findings on semaglutide addressing excess liver fat in people with obesity. The company also plans to present real-world evidence comparing major adverse cardiovascular events in adults with type 2 diabetes who escalate to semaglutide 2.0 mg versus those switching to tirzepatide. Martin Holst Lange, executive vice president of Research & Development and chief scientific officer, emphasized that these findings have the potential to shape the next generation of cardiometabolic care. The event will feature oral presentations on CagriSema, zenagamtide, Wegovy® (both injection and tablets), and UBT251. Novo Nordisk is hosting an International Press Briefing on September 30, 2026, which will be accessible via webcast to share the breadth and progression of its portfolio.